VANCOUVER and MINNEAPOLIS, Feb. 05, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Journal of the American Heart Association has published an article entitled, “Angina Severity, Mortality, and Healthcare Utilization Among Veterans with Stable Angina”. The prestigious journal is the official publication of […]
Author: Ken Dropiewski
DAXOR CORPORATION AWARDED GRANT FROM THE CENTER FOR ADVANCING POINT OF CARE TECHNOLOGIES (CAPCAT) TO DEVELOP A POINT-OF-CARE BLOOD VOLUME ANALYZER
NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a grant from the Center for Advancing Point of Care Technologies (CAPCaT), a program run by the Massachusetts Medical Device Development Center […]
Silence Therapeutics plc Announces $45 Million Private Placement
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. IN ADDITION, MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED […]
BD Announces First Fiscal Quarter Results; Raises Fiscal 2021 Guidance
– First fiscal quarter revenues of $5.315 billion grew 25.8% on a reported basis. On a currency-neutral basis, revenues increased 24.3%. – BD’s COVID-19 testing sales of $867 million contributed 20.5 percentage points to revenue growth on a reported basis. This includes BD Veritor™ Plus System revenues of $688 million. […]
Windtree Strengthens Its Board by Appointing Three New Directors
Company welcomes Dr. Evan Loh, Ms. Leslie Williams and Dr. Rob Scott, seasoned executives with deep cardiovascular development and commercial experience WARRINGTON, Pa., Feb. 4, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today […]
B-Secur Receives FDA Regulatory Clearance For Its HeartKey® EKG/ECG Technology
Expands portfolio across Health, Wellness and User Identification for deployment in consumer and medical technology sectors BELFAST, Northern Ireland–(BUSINESS WIRE)–B-Secur, a leader in EKG/ECG technology, today announced that it has received U.S. Food and Drug Administration (FDA) 510(K) clearance of its HeartKey® software library1. B-Secur’s HeartKey® is a suite of powerful […]
Mentice publishes the company’s year-end report for the period January-December 2020
STOCKHOLM, Feb. 4, 2021 /PRNewswire/ — Strong order intake and substantial improvement of the company’s order book as well as operating cash flowFourth quarter (October-December 2020) Order intake amounted to 73.1 (54.7) MSEK. Net sales amounted to 45.9 (60.2) MSEK. Operating income for the period before depreciations (EBITDA) totalled 4.3 (11.8) MSEK. Net […]
Sequana Medical Announces Granting of Key alfapump DSR® Patents in U.S. and Europe
GHENT, Belgium, Feb. 04, 2021 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces the granting of key patents for the alfapump DSR (Direct Sodium Removal) programme in the U.S. and European Union. […]
InspireMD Announces Pricing of Upsized $18 Million Underwritten Public Offering
TEL AVIV, Israel, Feb. 04, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (“InspireMD”) (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East and Asia, today announced the pricing […]
Idorsia announces financial results for 2020 – a successful year marked by outstanding clinical data
Allschwil, Switzerland – February 4, 2021 Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year 2020. Business highlights Positive results in the Phase 3 program of daridorexant, demonstrating improved overall sleep and daytime functioning of patients with insomnia Daridorexant new drug application (NDA) submitted to the […]



